Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Frequently asked questions
What sector does Ovid Therapeutics Inc (1OT) operate in?
Ovid Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ovid Therapeutics Inc (1OT) current stock price?
As of the latest data, Ovid Therapeutics Inc stock price is €1.89, with a previous close of €1.90. Ovid Therapeutics Inc lost -€0.01 in the last trading session, representing a -0.53% loss.
What is Ovid Therapeutics Inc (1OT) current market capitalization?
Ovid Therapeutics Inc market cap is approximately 369.11 million.
What is Ovid Therapeutics Inc (1OT) Earnings Per Share (EPS)?
The trailing EPS is -€0.20.
What is Ovid Therapeutics Inc (1OT) EBITDA?
Ovid Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -13.73 million.
Does Ovid Therapeutics Inc (1OT) pay dividends?
No. Ovid Therapeutics Inc does not pay a dividend.
When is Ovid Therapeutics Inc (1OT) next earnings report?
Ovid Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is Ovid Therapeutics Inc (1OT) beta (volatility) score?
Ovid Therapeutics Inc has a beta of 0.230, indicating lower volatility than the overall market.
